US and Europe Gene Editing Market to Grow at a CAGR of 18.2% to reach US$ 15,052.92 million from 2023 to 2030
The US and Europe gene editing market size is expected to reach US$ 15,052.92 million in 2030 from US$ 3,955.09 million in 2022; the market is estimated to record a CAGR of 18.2% during 2023–2030.
Market Insights and Analyst View:
Continuous technological advancements in gene editing tools, the availability of government funding, an upsurge in the number of genomics projects, and a rise in the prevalence of cancer and other genetic disorders are a major factor driving the US and Europe gene editing market growth. Growing preference for personalized medicine, increase in private and public sector funding, and rapid advancements in sequencing and gene editing techniques are a few of the factors that are likely to propel the US and Europe gene editing market growth in the coming years. Developments in CRISPR-based novel diagnostic tools to mitigate the adversities associated with the COVID-19 pandemic have benefitted the market in recent years. Key players in emerging economies and expanding fields of applications in several drug discovery studies are a few factors that provide notable opportunities to the US and Europe gene editing market players. In November 2020, Eli Lilly partnered with Precision BioSciences to use the ARCUS platform for the R&D of potential in vivo therapies for genetic disorders in collaboration with Durham, NC, a developer of therapies based on gene editing as well as “off-the-shelf” CAR T immunotherapies.
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Growth Drivers and Challenges:
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Rise in Prevalence of Cancer and Genetic Disorders
According to the World Health Organization (WHO), cancer was the cause of approximately 10 million deaths in the world in 2020. Overall, the global burden of cancer incidence and death is quickly increasing. As per the Centers for Disease Control and Prevention (CDC), in 2020, 1.6 million new cancers cases were reported, and 602,347 people died of cancer in the US. Hepatocellular carcinoma (HCC) is known to be the second leading cause of cancer-related deaths worldwide. According to the CDC, ~21,000 men and ~8,000 women develop liver cancer annually in the US. In 2021, 134,802 people in England died from cancer. The number of deaths has increased by 6% since 2001. As per the Macmillan Cancer Support, in 2022, ~3 million people had cancer in the UK; the number is expected to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040.
A chromosomal abnormality can be detected in nearly one out of every 150 live births. However, this is only a small fraction of chromosome mutations since most are lethal and result in prenatal death or stillbirth. 50% of all first-trimester miscarriages and 20% of all second-trimester miscarriages are estimated to involve a chromosomally abnormal fetus. Although Down syndrome is the most well-known and well-recognized autosomal trisomy, it is only diagnosed in ~1 out of every 800 live births.
Many cancer biology investigation groups are now using CRISPR as a standard approach. The CRISPR/Cas9 system has been observed to be effective in treating metastatic tumors. The CRISPR-LNP system contains a messenger RNA that translates the Cas9 CRISPR enzyme, which operates as molecular scissors to cut the DNA. CRISPR-based studies have opened new doors to treating hereditary or developmental neurological disorders (HNDs) such as fragile X syndrome and Down syndrome.
Thus, the increasing cases of cancer and genetic disorders propel the growth of the US and Europe gene editing market.
Report Segmentation and Scope:
The “US and Europe Gene Editing Market” is segmented on the basis of technology, product and service, application, end user, and geography. Based on technology, the market is segmented into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. The US and Europe gene editing market, by product and service, is segmented into reagents and consumables, instruments, and others. In terms of application, the US and Europe gene editing market is segmented into cell line engineering, genetic engineering, diagnostic application, drug discovery, and others. The US and Europe gene editing market, based on country, is segmented into the US and Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe).
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Segmental Analysis:
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Based on technology, the US and Europe gene editing market is categorized into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. In 2022, the CRISPR segment held the largest share of the market. Moreover, the same segment is also expected to register the fastest CAGR during the forecast period. The clustered regularly interspaced short palindromic repeats (CRISPR) are associated with Cas genes essential for adaptive immunity in selected bacteria and archaea. CRISPR enables organisms to respond to the changes and eliminate the invading genetic material. Three types of CRISPR mechanisms have been adopted for genome-editing protocols—wild-type Cas9, mutated Cas9, and nuclease-deficient Cas9.
CRISPR-Cas9 is faster, cheaper, and more accurate than other technologies of DNA editing and is used for a wide range of applications. It is considered the simplest, most versatile, and precise method of genetic manipulation. Sangamo Therapeutics, Editas Medicine, ThermoFisher Scientific, and Horizon Discovery Groups are among the companies that offer CRISPR tools and consumables associated with them.
US and Europe Gene Editing Market, by Technology – 2022 and 2030
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Based on application, the US and Europe gene editing market is categorized into cell line engineering, genetic engineering, diagnostic application, drug discovery, and others. In 2022, the cell line engineering segment held the largest market share. The market for the same segment is expected to grow at the fastest CAGR during the forecast period. Cell line engineering is majorly performed in laboratories, to understand the basic biology behind diseases and therapeutics. Cell line engineering provides benefits such as optimizing cell lines for recombinant protein expression and characterizing the protein profile of genetically modified organisms. Cell line engineering enables the production of various industrial and commercial products that gain much more revenue as the products are produced per the requirement.
Based on end user, the US and Europe gene editing market is segmented into pharmaceutical & biotechnology companies, academic and research institutes, contract research organizations (CROs), and others. In 2022, the pharmaceutical & biotechnology companies segment held the largest share of the market. The academic and research institutes segment is expected to register the highest CAGR during the forecast period. Academic and research institutes have developed various technologies in the field of genomics. For instance, the National Institutes of Health (NIH) and the United States Department of Agriculture (USDA) have developed a new technique that will aid in a more specific reconstruction of genomes, specifically in determining the sections of the genome coming from each parent. Findings regarding the new technique were published in the journal Nature Biotechnology. The gene editing market for the CRO segment is growing owing to the benefits conferred by outsourcing processing to CROs, especially in terms of cost-saving and time taken by research activities.
Regional Analysis:
The gene editing market in the US was valued at US$ 2,169.04 million in 2022 and is projected to reach US$ 8,376.43 million by 2030; it is expected to grow at a CAGR of 18.4% during the forecast period. The growth of the US and Europe gene editing market is driven by the increasing prevalence of genetic disorders and the rising adoption of advanced gene therapies to treat chronic diseases. According to the US Genetic and Rare Disease Information Center, ~1 in 10 people (~30 million) in the US have a genetic or rare disease. For instance, the data published by the NIH's National Library of Medicine in July 2021, cystic fibrosis is among the most common genetic diseases observed in the US population. The incidence rate for the disease is 1 in 2,500–3,500 newborns. However, the incidence of cystic fibrosis is relatively lower among other ethnic groups in the country. The disease incidence among these groups is ~1 in 17,000 African Americans and 1 in 31,000 Asian Americans. The rising adoption of cancer gene therapy for treatment and the introduction of associated products by the gene editing market players, along with the support by regulatory agencies for the commercialization of such products, are also expected to fuel the market growth in the US in the future. In May 2021, the US Food and Drug Administration (FDA) approved Lumakras (Sotorasib) as a targeted therapy for non-small cell lung cancer patients with tumors that express the G12C mutation in the KRAS gene.
According to SeedScientific, there are ~6,600 registered biotechnology companies and over 2,000 pharmaceutical companies in the US. In March 2021, scientists from the University of California (UC) San Francisco, UC Berkeley, and UC Los Angeles received approval from the FDA to jointly initiate an early phase, first-in-human gene editing clinical trial of a correction therapy for patients with sickle cell anemia using their own hematopoietic stem cells. In October 2020, Merck signed a license agreement with Takara Bio USA, Inc. Through this agreement, Merck licensed its CRISPR technology to Takara to develop vectors and other innovative products to facilitate research using CRISPR and cell engineering services, specifically stem cells. In February 2022, Integrated DNA Technologies, Inc (IDT, US) launched Alt-R HDR Donor Blocks to advance homology-driven repair gene editing research. IDT's Alt-R HDR Donor Blocks are an improved technique that is meant to increase the use of homology-directed repair (HDR) in vital studies of large fragments of DNA.
The European genome editing market is divided into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The market growth in the region is attributed to the growing life science research and the increase in investments in research and development.
Industry Developments and Future Opportunities:
Various initiatives taken by key players operating in the US and Europe gene editing market landscape are listed below:
- In March 2021, IDT, a leading comprehensive genomics solutions provider, announced the acquisition of Swift Biosciences, a pioneer in developing next-generation sequencing (NGS) library preparation genomics kits for academic, translational, and clinical research.
- In November 2022, ElevateBio, LLC unveiled its BaseCamp’s proprietary LentiPeak lentiviral vector platform. LentiPeak is a serum-free, suspension-based, scalable production platform that demonstrates high volumetric productivity of therapeutically relevant vector yields in adherence to regulatory guidelines. LentiPeak would enable an efficient transition for cell and gene therapies from the preclinical stage through clinical development and commercialization with accelerated timelines and reduced costs. The LentiPeak platform leverages ElevateBio BaseCamp’s end-to-end process, analytical development expertise, and scientific leadership in the gene editing market.
- In October 2022, Merck, a leading science and technology company, announced signing agreements licensing its CRISPR technology to two companies—PanCELLa, a cell therapy firm based in Toronto, Canada, and Takara Bio USA, Inc., a biotechnology company based in Mountain View, California, US.
COVID-19 Impact:
As per the study titled "Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening" published in the Journal Viruses in June 2022, researchers have described the creation of a suitable human cell line for the high-throughput testing of antiviral medications that target SARS-Cov-2. Angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), two essential host proteins required for viral entry into the host body, were engineered to express high levels in the human lung carcinoma cell line A549. The resultant development of more cell lines to manage COVID-19 had a significant impact on the US and Europe gene editing market in the last few years.
Competitive Landscape and Key Companies:
A few of the prominent players operating in the US and Europe gene editing market include Thermo Fisher Scientific Inc.; Merck KGaA; Lonza; PerkinElmer.; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; CRISPR Therapeutics; Editas Medicine; and ElevateBio. Thermo Fisher Scientific Inc. and Merck KGaA are the dominant players in the gene editing market. These companies focus on new product launches and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios. They have a widespread global presence, which allows them to serve a large set of customers, subsequently expanding their share in the US and Europe gene editing market.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Technology, Product and Service, Application, and End User
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The US and Europe gene editing market majorly consists of the players such as Thermo Fisher Scientific Inc.; Merck KGaA; Lonza; PerkinElmer.; Integrated DNA Technologies; GenScript; New England Biolabs; Eurofins Scientific; CRISPR Therapeutics; Editas Medicine; and ElevateBio among others.
The factors that are driving the growth of market are the rise in the prevalence of cancer and other genetic disorders and continuous technological advancements in gene editing tools. On the other hand, high cost of production of gene editing methods is likely to hinder the growth of the market during the forecast period.
Gene editing technique is utilized for the changes that are to be done in the DNA of a cell or an organism. The technique involves cutting DNA sequences for the addition or removing the DNA in the genome. The changes in the genome are done for the required characteristics of the cell. Genome editing is done for the research purpose, the treatment of the diseases, and the biotechnological purpose.
The US and Europe gene editing market is analyzed in the basis of technology, product and services, application, end user. Based on product, is segmented into CRISPR, TALEN, antisense, Zinc Finger Nucleases (ZFNs), and others. In 2022, the CRISPR segment held the largest share of the market. Moreover, the same segment is also expected to grow at the fastest rate during the coming years.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 US and Europe Gene Editing Market– By Technology
1.3.2 US and Europe Gene Editing Market– By Products and Services
1.3.3 US and Europe Gene Editing Market– By Application
1.3.4 US and Europe Gene Editing Market– By End User
1.3.5 Gene Editing Market– By Geography
2. Executive Summary
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. US and Europe Gene Editing Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 US – PEST Analysis
4.2.2 Europe – PEST Analysis
4.3 Expert Opinions
5. Gene Editing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rise in Prevalence of Cancer and Other Genetic Disorders
5.1.2 Continuous Technological Advancements in Gene Editing Tools
5.2 Market Restraints
5.2.1 High Cost of Production of Gene Editing Methods
5.3 Market Opportunities
5.3.1 Growing Biotechnology Industry in US and Europe
5.4 Future Trends
5.4.1 Strategic Initiatives by Market Players to Develop New Products
5.5 Impact Analysis
6. Gene Editing Market – US and Europe Analysis
6.1 US and Europe Gene Editing Market Revenue Forecast and Analysis
6.2 Market Positioning of Key Players
7. US and Europe Gene Editing Market Analysis – By Technology
7.1 Overview
7.1.1 US and Europe Gene Editing Market, By Technology 2022 & 2030 (%)
7.2 CRISPR
7.2.1 Overview
7.2.2 US and Europe CRISPR Market Revenue and Forecasts to 2030 (US$ Million)
7.3 TALEN
7.3.1 Overview
7.3.2 US and Europe TALEN Market Revenue and Forecasts to 2030 (US$ Million)
7.4 Antisense
7.4.1 Overview
7.4.2 US and Europe Antisense Market Revenue and Forecasts to 2030 (US$ Million)
7.5 Zinc Finger Nucleases (ZFNs)
7.5.1 Overview
7.5.2 US and Europe Zinc Finger Nucleases (ZFNs)Market Revenue and Forecasts to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)
8. US and Europe Gene Editing Market Analysis – By Products and Services
8.1 Overview
8.1.1 US and Europe Gene Editing Market, By Products and Services 2022 & 2030 (%)
8.2 Reagents and Consumables
8.2.1 Overview
8.2.2 US and Europe Reagents and Consumables Market Revenue and Forecasts to 2030 (US$ Million)
8.3 Instruments
8.3.1 Overview
8.3.2 US and Europe Instruments Market Revenue and Forecasts to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)
9. US and Europe Gene Editing Market Analysis – By Application
9.1 Overview
9.1.1 US and Europe Gene Editing Market, By Application 2022 & 2030 (%)
9.2 Cell Line Engineering
9.2.1 Overview
9.2.2 US and Europe Cell Line Engineering Market Revenue and Forecasts to 2030 (US$ Million)
9.3 Genetic Engineering
9.3.1 Overview
9.3.2 US and Europe Genetic Engineering Market Revenue and Forecasts to 2030 (US$ Million)
9.4 Diagnostic Application
9.4.1 Overview
9.4.2 US and Europe Diagnostic Application Market Revenue and Forecasts to 2030 (US$ Million)
9.5 Drug Discovery
9.5.1 Overview
9.5.2 US and Europe Drug Discovery Market Revenue and Forecasts to 2030 (US$ Million)
9.6 Others
9.6.1 Overview
9.6.2 US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)
10. US and Europe Gene Editing Market Analysis – By End User
10.1 Overview
10.1.1 US and Europe Gene Editing Market, By End User 2022 & 2030 (%)
10.2 Pharmaceutical & Biotechnology Companies
10.2.1 Overview
10.2.2 US and Europe Pharmaceutical & Biotechnology Companies Market Revenue and Forecasts to 2030 (US$ Million)
10.3 Academic and Research Institutes
10.3.1 Overview
10.3.2 US and Europe Academic and Research Institutes Market Revenue and Forecasts to 2030 (US$ Million)
10.4 Contract Research Organization (CROs)
10.4.1 Overview
10.4.2 US and Europe Contract Research Organization (CROs) Market Revenue and Forecasts to 2030 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)
11. US and Europe Gene Editing Market Analysis
11.1 US Gene Editing Market Revenue Forecast and Analysis
11.1.1 Overview
11.1.2 US: Gene Editing Market - Revenue and Forecasts to 2030 (USD Million)
11.1.3 US: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
11.1.4 US: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
11.1.5 US: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
11.1.6 US: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
11.2 Europe Gene Editing Market Revenue Forecast and Analysis
11.2.1 Overview
11.2.2 Europe: Gene Editing Market - Revenue and Forecasts to 2030 (USD Million)
11.2.3 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
11.2.4 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
11.2.5 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
11.2.6 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
11.2.7 Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Country (%)
11.2.8 Germany: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.8.1 Germany: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.8.2 Germany: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
11.2.8.3 Germany: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
11.2.8.4 Germany: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
11.2.8.5 Germany: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
11.2.9 UK: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.9.1 UK: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.9.2 UK: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
11.2.9.3 UK: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
11.2.9.4 UK: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
11.2.9.5 UK: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
11.2.10 France: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.10.1 France: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.10.2 France: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
11.2.10.3 France: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
11.2.10.4 France: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
11.2.10.5 France: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
11.2.11 Italy: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.11.1 Italy: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.11.2 Italy: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
11.2.11.3 Italy: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
11.2.11.4 Italy: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
11.2.11.5 Italy: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
11.2.12 Spain: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.12.1 Spain: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.12.2 Spain: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
11.2.12.3 Spain: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
11.2.12.4 Spain: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
11.2.12.5 Spain: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
11.2.13 Rest of Europe: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.13.1 Rest of Europe: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
11.2.13.2 Rest of Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Technology (USD Million)
11.2.13.3 Rest of Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Products and Services (USD Million)
11.2.13.4 Rest of Europe: Gene Editing Market- Revenue and Forecasts to 2030, By Application (USD Million)
11.2.13.5 Rest of Europe: Gene Editing Market- Revenue and Forecasts to 2030, By End User (USD Million)
12. Industry Landscape
12.1 Overview
12.2 Growth Strategies in US and Europe Gene Editing Market
12.3 Organic Growth Strategies
12.3.1 Overview
12.4 Inorganic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Thermo Fisher Scientific Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Merck KGaA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Lonza Group AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Horizon Discovery Group plc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Integrated DNA Technologies, Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 GenScript Biotech Corporation
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 New England Biolabs
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Eurofins Scientific SE
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CRISPR Therapeutics
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Editas Medicine Inc
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 ElevateBio LLC
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
14. Appendix
14.1 Glossary of Terms
List of Tables
Table 1. US: Gene Editing Market, By Technology – Revenue and Forecast to 2030 (USD Million)
Table 2. US: Gene Editing Market, By Products and Services – Revenue and Forecast to 2030 (USD Million)
Table 3. US: Gene Editing Market, By Application– Revenue and Forecast to 2030 (USD Million)
Table 4. US: Gene Editing Market, By End User– Revenue and Forecast to 2030 (USD Million)
Table 5. Europe: Gene Editing Market, By Technology – Revenue and Forecast to 2030 (USD Million)
Table 6. Europe: Gene Editing Market, By Products and Services – Revenue and Forecast to 2030 (USD Million)
Table 7. Europe: Gene Editing Market, By Application– Revenue and Forecast to 2030 (USD Million)
Table 8. Europe: Gene Editing Market, By End User– Revenue and Forecast to 2030 (USD Million)
Table 9. Germany: Gene Editing Market, By Technology – Revenue and Forecast to 2030 (USD Million)
Table 10. Germany: Gene Editing Market, By Products and Services – Revenue and Forecast to 2030 (USD Million)
Table 11. Germany: Gene Editing Market, By Application– Revenue and Forecast to 2030 (USD Million)
Table 12. Germany: Gene Editing Market, By End User– Revenue and Forecast to 2030 (USD Million)
Table 13. UK: Gene Editing Market, By Technology – Revenue and Forecast to 2030 (USD Million)
Table 14. UK: Gene Editing Market, By Products and Services – Revenue and Forecast to 2030 (USD Million)
Table 15. UK: Gene Editing Market, By Application– Revenue and Forecast to 2030 (USD Million)
Table 16. UK: Gene Editing Market, By End User– Revenue and Forecast to 2030 (USD Million)
Table 17. France: Gene Editing Market, By Technology – Revenue and Forecast to 2030 (USD Million)
Table 18. France: Gene Editing Market, By Products and Services – Revenue and Forecast to 2030 (USD Million)
Table 19. France: Gene Editing Market, By Application– Revenue and Forecast to 2030 (USD Million)
Table 20. France: Gene Editing Market, By End User– Revenue and Forecast to 2030 (USD Million)
Table 21. Italy: Gene Editing Market, By Technology – Revenue and Forecast to 2030 (USD Million)
Table 22. Italy: Gene Editing Market, By Products and Services – Revenue and Forecast to 2030 (USD Million)
Table 23. Italy: Gene Editing Market, By Application– Revenue and Forecast to 2030 (USD Million)
Table 24. Italy: Gene Editing Market, By End User– Revenue and Forecast to 2030 (USD Million)
Table 25. Spain: Gene Editing Market, By Technology – Revenue and Forecast to 2030 (USD Million)
Table 26. Spain: Gene Editing Market, By Products and Services – Revenue and Forecast to 2030 (USD Million)
Table 27. Spain: Gene Editing Market, By Application– Revenue and Forecast to 2030 (USD Million)
Table 28. Spain: Gene Editing Market, By End User– Revenue and Forecast to 2030 (USD Million)
Table 29. Rest of Europe: Gene Editing Market, By Technology – Revenue and Forecast to 2030 (USD Million)
Table 30. Rest of Europe: Gene Editing Market, By Products and Services – Revenue and Forecast to 2030 (USD Million)
Table 31. Rest of Europe: Gene Editing Market, By Application– Revenue and Forecast to 2030 (USD Million)
Table 32. Rest of Europe: Gene Editing Market, By End User– Revenue and Forecast to 2030 (USD Million)
Table 33. Recent Organic Growth Strategies in US and Europe Gene Editing Market
Table 34. Recent Inorganic Growth Strategies in the US and Europe Gene Editing Market
Table 35. Glossary of Terms, Gene Editing Market
List of Figures
Figure 1. Gene Editing Market Segmentation
Figure 2. Gene Editing Market Segmentation, by Region
Figure 3. US and Europe Gene Editing Market Overview
Figure 4. CRISPR Segment Held Largest Share of Gene Editing Market
Figure 5. UK to Show Significant Growth During Forecast Period
Figure 6. US and Europe Gene Editing Market – Leading Country Markets (US$ Million)
Figure 7. US and Europe Gene Editing Market, Industry Landscape
Figure 8. US PEST Analysis
Figure 9. Europe PEST Analysis
Figure 10. Gene Editing Market – Key Industry Dynamics
Figure 11. Gene Editing Market Impact Analysis of Drivers and Restraints
Figure 12. US and Europe Gene Editing Market – Revenue Forecast and Analysis – 2020–2030
Figure 13. Market Positioning of Key Players in US and Europe Gene Editing Market
Figure 14. US and Europe Gene Editing Market, By Technology 2022 & 2030 (%)
Figure 15. US and Europe Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Market Revenue and Forecasts to 2030 (US$ Million)
Figure 16. US and Europe TALEN Market Revenue and Forecasts to 2030 (US$ Million)
Figure 17. US and Europe Antisense Market Revenue and Forecasts to 2030 (US$ Million)
Figure 18. US and Europe Zinc Finger Nucleases (ZFNs) Market Revenue and Forecasts to 2030 (US$ Million)
Figure 19. US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)
Figure 20. US and Europe Gene Editing Market, By Products and Services 2022 & 2030 (%)
Figure 21. US and Europe Reagents and Consumables Market Revenue and Forecasts to 2030 (US$ Million)
Figure 22. US and Europe Instruments Market Revenue and Forecasts to 2030 (US$ Million)
Figure 23. US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)
Figure 24. US and Europe Gene Editing Market, By Application 2022 & 2030 (%)
Figure 25. US and Europe Cell Line Engineering Market Revenue and Forecasts to 2030 (US$ Million)
Figure 26. US and Europe Genetic Engineering Market Revenue and Forecasts to 2030 (US$ Million)
Figure 27. US and Europe Diagnostic Application Market Revenue and Forecasts to 2030 (US$ Million)
Figure 28. US and Europe Drug Discovery Market Revenue and Forecasts to 2030 (US$ Million)
Figure 29. US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)
Figure 30. US and Europe Gene Editing Market, By End User 2022 & 2030 (%)
Figure 31. US and Europe Pharmaceutical & Biotechnology Companies Market Revenue and Forecasts to 2030 (US$ Million)
Figure 32. US and Europe Academic and Research Institutes Market Revenue and Forecasts to 2030 (US$ Million)
Figure 33. US and Europe Contract Research Organization (CROs) Market Revenue and Forecasts to 2030 (US$ Million)
Figure 34. US and Europe Others Market Revenue and Forecasts to 2030 (US$ Million)
Figure 35. US Gene Editing Market– Revenue Forecast and Analysis – 2020- 2030
Figure 36. Europe Gene Editing Market– Revenue Forecast and Analysis – 2020- 2030
Figure 37. Europe: Gene Editing Market -Revenue and Forecasts to 2030, By Country (%)
Figure 38. Germany: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
Figure 39. UK: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
Figure 40. France: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
Figure 41. Italy: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
Figure 42. Spain: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
Figure 43. Rest of Europe: Gene Editing Market – Revenue and Forecast to 2030 (USD Million)
Figure 44. Growth Strategies in US and Europe Gene Editing Market
The List of Companies - US and Europe Gene Editing Market
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Lonza Group AG
- Horizon Discovery Group plc.
- INTEGRATED DNA TECHNOLOGIES, INC.
- GenScript Biotech Corporation
- New England Biolabs
- Eurofins Scientific SE
- CRISPR Therapeutics
- Editas Medicine Inc
- ElevateBio LLC
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For